DAVID CHARLES FESTUS MOFFAT,STÉPHANE PINTAT,STEPHEN DAVIES
申请号：
PT07732629
公开号：
PT2013175T
申请日:
2007.05.01
申请国别(地区):
PT
年份:
2017
代理人:
摘要：
Compounds of formula (I) are inhibitors of p38 MAP kinase, and are therefore of utility in the treatment of, inter alia, inflammatory conditions including rheumatoid arthritis and COPD: wherein: G is &mdashN&boxH or &mdashCH&boxH D is an optionally substituted divalent mono- or bi-cyclic aryl or heteroaryl radical having 5-13 ring members R6 is hydrogen or optionally substituted C1-C3 alkyl P represents hydrogen and U represents a radical of formula (IA) or U represents hydrogen and P represents a radical of formula -A-(CH2)z&mdashX1-L1-Y&mdashNH&mdashCHR1R2 wherein A represents an optionally substituted divalent mono- or bicyclic carbocyclic or heterocyclic radical having 5-13 ring members z, Y, L1, and X1 are as defined in the specification R1 is a carboxylic acid group (&mdashCOOH), or an ester group which is hydrolysable by one or more intracellular esterase enzymes to a carboxylic acid group and R2 is the side chain of a natural or non-natural alpha amino acid.
